Prognostic value of bone marrow microvessel density and angiogenic cytokines in patients with multiple myeloma undergoing autologous stem cell transplant

References

• Tricot G. Multiple myeloma and other plasma cell disorders. Hematology basic principles and practice. In: Hoffman R, editor. 4th edPhiladelphia: Elsevier Churchill Livingstone2005. pp 1501–1535.
   Google Scholar
• Child JA, Morgan GJ, Davies FE, High dose chemotherapy with hematopoietic stem cell rescue for multiple myeloma. N Engl J Med 2003;348:1875–1883.
   PubMed Web of Science ®Google Scholar
• Attal M, Harousseau JL, Stoppa AM, A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. Intergroupe Francais du Myeloma. N Engl J Med 1996;335:91–97.
   PubMed Web of Science ®Google Scholar
• Folkman J. Seminars in medicine of the Beth Israel Hospital, Boston. Clinical applications of research on angiogenesis. N Engl J Med 1995;333:1757–1763.
   PubMed Web of Science ®Google Scholar
• Nyberg P, Salo T, Kalluri R. Tumor microenvironment and angiogenesis. Front Biosci 2008;13:6537–6553.
   PubMed Web of Science ®Google Scholar
• Hicklin DJ, Ellis LM. Role of the vascular endothelial growth factor pathway in tumour growth and angiogenesis. J Clin Oncol 2005;23:1011–1027.
   PubMed Web of Science ®Google Scholar
• Kerbel RS. Tumor angiogenesis:past, present and the near future. Carcinogenesis 2000;21:505–515.
   PubMed Web of Science ®Google Scholar
• Moehler TM, Neben K, Ho AD, Goldschmidt H. Angiogenesis in hematologic malignancies. Ann Hematol 2001;80:695–705.
   PubMed Web of Science ®Google Scholar
• Kuzu I, Beksac M, Arat M, Celebi H, Elhan AH, Erekul S. Bone marrow microvessel density (MVD) in adult acute myeloid leukemia (AML): therapy induced changes and effects on survival. Leuk Lymphoma 2004;45:1185–1190.
   PubMed Web of Science ®Google Scholar
• Kini AR, Kay NE, Peterson LC. Increased bone marrow angiogenesis in B cell chronic lymphocytic leukmia. Leukemia 2000;14:1414–1418.
   PubMed Web of Science ®Google Scholar
• Korkolopoulou P, Viniou N, Kovantzos N, Clinicopathologic correlations of bone marrow angiogenesis in chronic myeloid leukemia: a morphometric study. Leukemia 2003;17:89–97.
   PubMed Web of Science ®Google Scholar
• Pruneri G, Bertolini F, Soligo D, Angiogenesis in myelodysplastic syndromes. Br J Cancer 1999;81:398–401.
   Web of Science ®Google Scholar
• Vacca A, Ribatti D, Roncali L, Bone marrow angiogenesis and progression in multiple myeloma. Br J Haematol 1994;87:503–508.
   PubMed Web of Science ®Google Scholar
• Vacca A, Ribatti D, Presta M, Bone marrow neovascularization, plasma cell angiogenic potential, and matrix metalloproteinase-2 secretion parallel progression of human multiple myeloma. Blood 1999;93:3064–3073.
   PubMed Web of Science ®Google Scholar
• Rajkumar SV, Leong T, Roche PC, Prognostic value of bone marrow angiogenesis in multiple myeloma. Clin Cancer Res 2000;6:3111–3116.
   PubMed Web of Science ®Google Scholar
• Sezer O, Niemöller K, Eucker J, Bone marrow microvessel density is a prognostic factor for survival in patients with multiple myeloma. Ann Hematol 2000;79:574–577.
   PubMed Web of Science ®Google Scholar
• Munshi NC, Wilson C. Increased bone marrow microvessel density in newly diagnosed multiple myeloma carries a poor prognosis. Semin Oncol 2001;28:565–569.
   PubMed Web of Science ®Google Scholar
• Ahn MJ, Park CK, Choi JH, Clinical significance of microvessel density in multiple myeloma patients. J Korean Med Sci 2001;16:45–50.
   PubMed Web of Science ®Google Scholar
• Ribas C, Colleoni GWB, Silva MRR, Carregoza MJ, Bordin JO. Prognostic significance of vascular endothelial growth factor immunoexpression in the contex of adverse standard prognostic factors in multiple myeloma. Eur J Haematol 2004;73:311–317.
   PubMed Web of Science ®Google Scholar
• Rajkumar SV, Fonseca R, Witzig TE, Gertz MA, Greipp PR. Bone marrow angiogenesis in patients achieving complete response after stem cell transplantation for multiple myeloma. Leukemia 1999;13:469–472.
   PubMed Web of Science ®Google Scholar
• Kumar S, Gertz MA, Dispenzieri A, Prognostic value of bone marrow angiogenesis in patients with multiple myeloma undergoing high dose therapy. Bone Marrow Transplant 2004;34:235–239.
   PubMed Web of Science ®Google Scholar
• Sezer O, Jakob C, Eucker J, Serum levels of the angiogenic cytokines basic fibroblast growth factor (bFGF), vascular endothelial growth factor (VEGF) and hepatocyte growth factor (HGF) in multiple myeloma. Eur J Haematol 2001;66:83–88.
   PubMed Web of Science ®Google Scholar
• Alexandrakis MG, Passam FH, Boula A, Relationship betwen circulating serum soluble interleukin-6 receptor and the angiogenic cytokines basic fibroblast growth factor and vascular endothelial growth factor in multiple myeloma. Ann Hematol 2003;82:19–23.
   PubMed Web of Science ®Google Scholar
• Kumar S, Witzig TE, Timm M, Bone marrow angiogenic ability and expression of angiogenic cytokines in myeloma: evidence favoring loss of marrow angiogenesis inhibitory activity with disease progression. Blood 2004;104:1159–1165.
   PubMed Web of Science ®Google Scholar
• Andersen NF, Standal T, Nielsen JL, Syndecan-1 and angiogenic cytokines in multiple myeloma: correlation with bone marrow angiogenesis and survival. Br J Haematol 2005;128:210–217.
   PubMed Web of Science ®Google Scholar
• Jakob C, Sterz J, Zavrski I, Angiogenesis in multiple myeloma. Eur J Cancer 2006;42:1581–1590.
   PubMed Web of Science ®Google Scholar
• Cibeira MT, Rozman M, Segarra M, Bone marrow angiogenesis and angiogenic factors in multiple myeloma treated with novel agents. Cytokine 2008;41:244–253.
   PubMed Web of Science ®Google Scholar
• Durie BGM, Salmon SE. A clinical staging system for multiple myeloma. Cancer 1975;36:842–854.
   PubMed Web of Science ®Google Scholar
• Greipp PR, San Miguel J, Durie BG, International staging system for multiple myeloma. J Clin Oncol 2005;23:3412–20.
   PubMed Web of Science ®Google Scholar
• Blade J, Samson D, Reece D, Criteria for evaluating disease response and progression in patients with multiple myeloma treated by high-dose therapy and haemopoietic stem cell transplantation. Myeloma Subcommittee of the EBMT. European Group for Blood and Marrow Transplant. Br J Haematol 1998;102:1115–1123.
   PubMed Web of Science ®Google Scholar
• Rizzieri DA, Wadleigh M, Wikstrand CJ, Tenascin and microvessel stromal changes in patients with non-Hodgkin's lymphoma are isolated to the sites of disease and vary in correlation to disease activity. Leuk Lymphoma 2005;46:1455–1462.
   PubMed Web of Science ®Google Scholar
• Hatjiharissi E, Terpos E, Papaioannou M, The combination of intermediate doses of thalidomide and dexamethasone reduces bone marrow microvessel density but not serum level of angiogenic cytokines in patients with refractory/relapsed multiple myeloma. Hematol Oncol 2004;22:159–168.
   PubMed Web of Science ®Google Scholar
• Vacca A, Ribatti D, Roccaro AM, Frigeri A, Dammacco F. Bone marrow angiogenesis in patients with active multiple myeloma. Semin Oncol 2001;28:543–550.
   PubMed Web of Science ®Google Scholar
• Sezer O, Niemöller K, Kaufmann O, Decrease of bone marrow angiogenesis in myeloma patients achieving a remission after chemotherapy. Eur J Haematol 2001;66:238–244.
   PubMed Web of Science ®Google Scholar
• Rajkumar SV, Mesa RA, Fonseca R, Bone marrow angiogenesis in 400 patients with monoclonal gammopathy of undetermined significance, multiple myeloma, and primary amyloidosis. Clin Cancer Res 2002;8:2210–2216.
   PubMed Web of Science ®Google Scholar
• Pruneri G, Ponzoni M, Ferreri AJ, Microvessel density, a surrogate marker of angiogenesis, is significantly related to survival in multiple myeloma patients. Br J Haematol 2002;118:817–820.
   PubMed Web of Science ®Google Scholar
• Alexandrakis MG, Passam FJ, Ganotakis E, Bone marrow microvascular density and angiogenic growth factors in multiple myeloma. Clin Chem Lab Med 2004;42:1122–1126.
   PubMed Web of Science ®Google Scholar
• Sezer O, Niemöller K, Jakob C, Relationship between bone marrow angiogenesis and plasma cell infiltration and serum beta2-microglobulin levels in patients with multiple myeloma. Ann Hematol. 2001;80:598–601.
   PubMed Web of Science ®Google Scholar
• Thompson MA, Witzig TE, Kumar S, Plasma levels of tumour necrosis factor alpha and interleukin-6 predict progression-free survival following thalidomide therapy in patients with previously untreated multiple myeloma. Br J Haematol 2003;123:305–308.
   PubMed Web of Science ®Google Scholar
• Niemöller K, Jakob C, Hider U, Bone marrow angiogenesis and its correlation with other disease characteristics in multiple myeloma in stage I versus stage II-III. J Cancer Res Clin Oncol 2003;129:234–238.
   PubMed Web of Science ®Google Scholar
• Kumar S, Witzig TE, Greipp PR, Rajkumar SV. Bone marrow angiogenesis and circulating plasma cells in multiple myeloma. Br J Haematol 2003;122:272–274.
   PubMed Web of Science ®Google Scholar
• Alexandrakis MG, Sfiridaki A, Miyakis S, Relationship between serum levels of vascular endothelial growth factor, hepatocyte growth factor and matrix metalloproteinase-9 with biochemical markers of bone disease in multiple myeloma. Clin Chim Acta 2007;379:31–35.
   PubMed Web of Science ®Google Scholar
• Mileshkin L, Honemann D, Gambell P, Patients with multiple myeloma treated with thalidomide: evaluation of clinical parameters, cytokines, angiogenic markers, mast cells and marrow CD57+ cytotoxic T cells as predictors of outcome. Haematologica 2007;92:1075–1082.
   PubMed Web of Science ®Google Scholar
• Ludwig H, Adam Z, Tothova E, Thalidomide maintenance treatment increases progression-free but not overall survival in elderly patients with myeloma. Haematologica 2010;95:1548–1554.
   PubMed Web of Science ®Google Scholar
• Ghobrial IM, Stewart AK. ASH evidence based guidelines: what is the role of maintenance therapy in the treatment of multiple myeloma? Hematology Am Soc Hematol Educ Program 2009;587–589.
   PubMedGoogle Scholar